A burden of illness study for neuropathic pain in Europe
- PMID: 27217785
- PMCID: PMC4853004
- DOI: 10.2147/CEOR.S81396
A burden of illness study for neuropathic pain in Europe
Abstract
Purpose: Neuropathic pain (NP) is often severe and represents a major humanistic and economic burden. This study aimed at providing insight on this burden across France, Germany, Italy, Spain, and the UK, considering direct and indirect costs, productivity loss, and humanistic impact on patients and their families.
Methods: Physician questionnaires provided data on patients presenting with NP covering demographics, sick leave and retirement, number of consultations, drug treatments, and surgical procedures. Patients provided further demographic and disease-related data and completed the Work Productivity and Activity Impairment (WPAI), the EuroQol 5-Dimension (EQ-5D), and the Brief Pain Inventory (BPI) questionnaires. All health-related direct unitary costs were collected from relevant country-specific sources and adjusted to 2012 prices (€) where necessary. A subgroup analysis of costs based on diabetic peripheral neuropathy (n=894), fibromyalgia (n=300), and low back pain (n=963) was performed.
Findings: About 413 physicians completed a total of 3,956 patient records forms. Total annual direct health-care costs per patient ranged from €1,939 (Italy) to €3,131 (Spain). Annual professional caregiver costs ranged from €393 (France) to €1,242 (UK), but this only represented a small proportion of total care because much care is provided by family or friends. Sick leave costs ranged from €5,492 (UK) to €7,098 (France), with 10%-32% patients prevented from working at some point by NP. Total cost (including direct and indirect costs) of NP per patient was €10,313 in France (69% of the total cost), €14,446 in Germany (78%), €9,305 in Italy (69%), €10,597 in Spain (67%), and €9,685 in the UK (57%). Indirect costs (ie, sick leave) constituted the majority of costs in all five countries: €7,098 in France, €11,232 in Germany, €6,382 in Italy, €7,066 in Spain, and €5,492 in the UK. In the subgroup analysis, total annual direct costs per patient were highest for neuropathic back pain and radiculopathy, and lowest for fibromyalgia. Mean WPAI score range was 34.4-56.1; BPI interference was 4.1-4.8; and EQ-5D was 0.57-0.74. The results suggest that a significant proportion of the patient's work time in the previous week was affected by NP, and these are relatively high compared with other diseases such as diabetes, respiratory conditions, and arthritis.
Implications: Despite differences in practice between countries, these findings suggest a high opportunity cost for society in terms of lost work and productivity due to NP. The wider costs appear significantly higher to patients, carers/families, and society as a whole than to the health system alone.
Keywords: burden of illness; chronic lower back pain; neuropathic pain; productivity.
Figures
Similar articles
-
Social/economic costs and health-related quality of life in patients with juvenile idiopathic arthritis in Europe.Eur J Health Econ. 2016 Apr;17 Suppl 1:79-87. doi: 10.1007/s10198-016-0786-1. Epub 2016 Apr 16. Eur J Health Econ. 2016. PMID: 27086322
-
Social/economic costs and quality of life in patients with haemophilia in Europe.Eur J Health Econ. 2016 Apr;17 Suppl 1:53-65. doi: 10.1007/s10198-016-0785-2. Epub 2016 Apr 5. Eur J Health Econ. 2016. PMID: 27048374
-
Cost of non-alcoholic steatohepatitis in Europe and the USA: The GAIN study.JHEP Rep. 2020 Jul 15;2(5):100142. doi: 10.1016/j.jhepr.2020.100142. eCollection 2020 Oct. JHEP Rep. 2020. PMID: 32775976 Free PMC article.
-
Neuropathic pain: quality-of-life impact, costs and cost effectiveness of therapy.Pharmacoeconomics. 2009;27(2):95-112. doi: 10.2165/00019053-200927020-00002. Pharmacoeconomics. 2009. PMID: 19254044 Review.
-
The epidemiology, economic burden, and pharmacological treatment of chronic low back pain in France, Germany, Italy, Spain and the UK: a literature-based review.Expert Opin Pharmacother. 2009 Nov;10(16):2581-92. doi: 10.1517/14656560903304063. Expert Opin Pharmacother. 2009. PMID: 19874246 Review.
Cited by
-
Neuropathic Pain in Neurologic Disorders: A Narrative Review.Cureus. 2022 Feb 20;14(2):e22419. doi: 10.7759/cureus.22419. eCollection 2022 Feb. Cureus. 2022. PMID: 35345699 Free PMC article. Review.
-
Estimating the broader fiscal consequences of acute hepatic porphyria (AHP) with recurrent attacks in Belgium using a public economic analytic framework.Orphanet J Rare Dis. 2021 Aug 4;16(1):346. doi: 10.1186/s13023-021-01966-3. Orphanet J Rare Dis. 2021. PMID: 34348763 Free PMC article.
-
Endothelin-1 Decreases Excitability of the Dorsal Root Ganglion Neurons via ETB Receptor.Mol Neurobiol. 2018 May;55(5):4297-4310. doi: 10.1007/s12035-017-0640-1. Epub 2017 Jun 16. Mol Neurobiol. 2018. PMID: 28623618
-
Noninvasive multimodal fluorescence and magnetic resonance imaging of whole-organ intervertebral discs.Biomed Opt Express. 2021 May 7;12(6):3214-3227. doi: 10.1364/BOE.421205. eCollection 2021 Jun 1. Biomed Opt Express. 2021. PMID: 34221655 Free PMC article.
-
Changes in pain and concurrent pain medication use following compounded topical analgesic treatment for chronic pain: 3- and 6-month follow-up results from the prospective, observational Optimizing Patient Experience and Response to Topical Analgesics study.J Pain Res. 2017 Oct 3;10:2341-2354. doi: 10.2147/JPR.S143513. eCollection 2017. J Pain Res. 2017. PMID: 29042810 Free PMC article.
References
-
- Health in the European Union: special eurobarometer 272. European Commission; 2007. [Accessed January 11, 2016]. Available from: http://ec.Europa.Eu/health/ph_publication/eb_health_en.Pdf.
-
- International Association for the Study of Pain Iasp taxonomy. [Accessed February 10, 2015]. Available from: http://www.iasp-pain.org/Taxonomy?navItemNumber=576.
-
- Treede R-D, Jensen TS, Campbell J, et al. Neuropathic pain redefinition and a grading system for clinical and research purposes. Neurology. 2008;70(18):1630–1635. - PubMed
-
- Freynhagen R, Baron R, Gockel U, Tolle TR. Paindetect: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin. 2006;22(10):1911–1920. - PubMed
-
- Freynhagen R, Baron R. The evaluation of neuropathic components in low back pain. Curr Pain Headache Rep. 2009;13(3):185–190. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous